Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PharmaCord to boost pharma services with Permira’s investment
The investment is managed by the funds of Permira and is expected to close by the fourth quarter of 2024, subject to necessary approvals and conditions. The companies
The investment is managed by the funds of Permira and is expected to close by the fourth quarter of 2024, subject to necessary approvals and conditions. The companies
Currently, AGMB-447 is being assessed in an ongoing Phase I clinical trial as a potential treatment for IPF. The single-centre, integrated trial aims to evaluate the safety, tolerability,
Fast Track process of the FDA is intended to accelerate the development and review of drugs that address serious conditions and fill unmet medical needs. Lunresertib along with
The Department of Health (DoH) Abu Dhabi in the UAE has entered into a memorandum of understanding (MoU) with Pfizer Gulf to bolster research in areas including sickle
TLX250-CDx (Zircaix) is the company’s investigational radiodiagnostic PET agent for the renal masses characterisation as ccRCC or non-ccRCC in a non-invasive manner. Initiated in December 2023, the rolling
The company also launched AutoIND, an AI-powered platform designed to optimise the drafting, reviewing, and submitting of regulatory documents in drug development. AutoIND is the first product on
Octopus Ventures and Redalpine co-led the investment round with contributions from Wilbe Capital, BlueYard Capital, Acequia Capital, Amino Collective, and Hawktail. This funding is set to accelerate the
The funding round was spearheaded by existing investors Engine Ventures and Safar Partners, with new participations from Bill Gates, Parkinson’s UK, and the Michael J. Fox Foundation, which
Under the terms of the agreement, RevolKa will utilise its protein engineering platform, aiProtein, integrated with artificial intelligence (AI), to create and deliver highly functional proteins. The companies
Denosumab has secured approval in several countries and regions under different trade names for a range of several indications such as for osteoporosis treatment in postmenopausal women who